Drug intelligence / Profile preview

XPRO9523

Development stage: Preclinical
Lead developer: Zenas BioPharma
Modality: Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

XPRO9523 is a preclinical Fc-engineered antibody developed by Xencor and licensed to Zenas BioPharma. It is being developed for the treatment of autoimmune diseases. Zenas BioPharma holds exclusive worldwide rights for its development and commercialization.

Targets

FCGRT (Neonatal crystallizable fragment receptor)CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)

Beyond the preview

Go deeper on XPRO9523.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XPRO9523.

Explore the full profile